Elastin-like polypeptides: A strategic fusion partner for biologics.
Elastin-like peptides (ELPs) are derivatives of tropoelastin with a unique property that allows them to stay soluble below a certain critical temperature but reversibly form aggregates above that temperature. Since they are derived from tropoelastin, ELPs are biocompatible, non-toxic, and non-immunogenic. The unique properties of ELPs have made them a desirable class of fusion tags used in several biomedical applications including targeted drug delivery and enhancing the half-life of protein drugs. The most significant property of an ELP is that when fused to other proteins, the phase transition property of the ELP is maintained, and the target protein can be purified using the thermally driven property of the ELP. The ELP tag purification process is simple and inexpensive, and involves cycling the protein above and below the transition temperature of the ELP fusion followed by centrifugation to obtain the desired protein, without any need for chromatography. Consequently, using ELPs as a purification tag should be potentially interesting to biopharmaceutical companies who spend a significant percentage of their manufacturing costs on expensive protein purification techniques such as chromatography and filtration. However, ELP tags have not yet been used for commercial protein purification due to some challenges of translating this technique, which has been demonstrated mostly in academic laboratories, to a biotechnology manufacturing environment. The article first reviews the state-of-the-art in protein "ELPylation," and discusses some applications which have benefitted from using ELP as a fusion tag. Then, the article discusses the main advantages of using ELP as a purification tag, and evaluates the remaining hurdles for its implementation in industrial protein production. Biotechnol. Bioeng. 2016;113: 1617-1627. © 2016 Wiley Periodicals, Inc.
Department of Chemical and Biochemical Engineering, Rutgers University, Piscataway, New Jersey.
Agnes
A
Yeboah
Department of Biomedical Engineering, Rutgers University, 599 Taylor Road, Piscataway 08854, New Jersey.
Rick I
RI
Cohen
Department of Biomedical Engineering, Rutgers University, 599 Taylor Road, Piscataway 08854, New Jersey.
Charles
C
Rabolli
Department of Biomedical Engineering, Rutgers University, 599 Taylor Road, Piscataway 08854, New Jersey.|Center for Engineering in Medicine, Massachusetts General Hospital and Shriners Burns Hospital, Boston, Massachusetts.
Martin L
ML
Yarmush
Department of Biomedical Engineering, Rutgers University, 599 Taylor Road, Piscataway 08854, New Jersey. fberthia@rci.rutgers.edu.
Francois
F
Berthiaume
D016503:Drug Delivery Systems; D004549:Elastin / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D010455:Peptides / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism
D010455:Peptides; D011993:Recombinant Fusion Proteins; D004549:Elastin
ELPylation; biologics; biopharmaceutical; elastin-like peptides (ELP); purification